🇺🇸 FDA
Patent

US 11690850

Inhibitors of receptor interacting protein kinase I for the treatment of disease

granted A61KA61K31/50A61K31/501

Quick answer

US patent 11690850 (Inhibitors of receptor interacting protein kinase I for the treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/50, A61K31/501, A61K31/506, A61K31/55